FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:2291-2293 May 25, 2006 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Muthukumar, T. PubMed Citation

To the Editor: The observations of Muthukumar et al. (Dec. 1 issue)¹ regarding the clinical usefulness of FOXP3 messenger RNA (mRNA) in predicting the outcome of renal-allograft rejection are thought-provoking, but we believe caution is needed. Although data from their study suggest that levels of FOXP3 mRNA in urine are the best prognostic indicator of reversal of acute rejection, there is substantial overlap in values between the patient groups (as shown in Figure 2 of the article). In addition, the overlapping confidence intervals for the areas under the receiver-operating-characteristic (ROC) curves (shown in Figure 3 of the article) suggest the . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.